Author

K. Lester

Institution: Royal College of Surgeons in Ireland

Observed institutions: University of North Carolina at Chapel Hill, Royal College of Surgeons in Ireland, SUNY Upstate Medical University, Children's Health Ireland at Crumlin, National Children’s Research Centre

OpenAlex ID: A5010232701

ePS6.10 A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis

2022 · S. Sutton, J. Hayden, et al. · Journal of Cystic Fibrosis · 3

P057 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) aged 6–11 years – the RECOVER study

2024 · S. Sutton, J. Hayden, et al. · Journal of Cystic Fibrosis · 2

105 Elexacaftor/Tezacaftor/Ivacaftor is associated with improvements in mucus plugging, air trapping and bronchial thickening but not bronchial widening in people with CF aged 12 years and older

2025 · P. McNally, R. Cregan, et al. · Journal of Cystic Fibrosis · 1

EPS4.01 Impact of 18 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with CF – the RECOVER study

2024 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis · 1

WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years

2024 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis · 1

485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study

2023 · S. Sutton, J. Hayden, et al. · Journal of Cystic Fibrosis · 1

PDF

Poster: 115ENHANCE: Establishing Natural History in an Advanced New CF Care Era

2026 · K. Lester, P. McNally, et al. · Journal of Cystic Fibrosis

Poster: 119Improvement in abdominal symptoms and gut inflammation over 24 months of treatment with elexacaftor/tezacaftor/ivacaftor in people with CF aged 6 and older - results from the RECOVER study

2026 · P. McNally, J. Davies, et al. · Journal of Cystic Fibrosis

P371 Introducing the ENHANCE study – establishing the natural history of childhood CF in a new era of care

2025 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis

WS19.03 Improvements in structural lung disease over 24 months in children with CF aged 6-11 on elexacaftor/tezacaftor/ivacaftor (ETI) – interim analysis using automated LungQ scoring

2025 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis

EPS4.02 Exploring barriers to treatment adherence in people with cystic fibrosis: insights from the RECOVER study at 24 months

2024 · S. Sutton, J. Hayden, et al. · Journal of Cystic Fibrosis

WS13.01 Proteomic analysis of nasal lavage fluid samples in people with cystic fibrosis after one year of treatment with elexacaftor/ivacaftor/tezacaftor – the RECOVER study

2024 · S. Nolan, S. Weldon, et al. · Journal of Cystic Fibrosis

WS04.05 Sustained improvement in abdominal symptoms measured by the CFAbd-Score over 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in people with CF aged ≥12 years: results from the RECOVER study

2024 · P. McNally, J.C. Davies, et al. · Journal of Cystic Fibrosis

547 Reduction in abdominal symptoms measured by Cystic Fibrosis Abdomen-score over 6 months of treatment with elexacaftortezacaftor-ivacaftor in children with cystic fibrosis aged 6 to 11: early results from the RECOVER study

2023 · P. McNally, J. Davies, et al. · Journal of Cystic Fibrosis

PDF

142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11

2023 · K. Lester, P. McNally, et al. · Journal of Cystic Fibrosis

PDF

140 Rhinosinusitis outcomes in people with cystic fibrosis after 6 months of elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study

2023 · R. Stone, K. Lester, et al. · Journal of Cystic Fibrosis

PDF

144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study

2023 · K. Lester, P. McNally, et al. · Journal of Cystic Fibrosis

PDF

138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study

2023 · S. Sutton, P. McNally, et al. · Journal of Cystic Fibrosis

PDF

196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study

2023 · S. Nolan, S. Weldon, et al. · Journal of Cystic Fibrosis

PDF

P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study

2023 · R.G. Stone, S. Sutton, et al. · Journal of Cystic Fibrosis

PDF

EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study

2023 · J.G. Mainz, K. Lester, et al. · Journal of Cystic Fibrosis

PDF

P170 Trikafta® modulates release of extracellular vesicles in cystic fibrosis

2023 · N. Lakkappa, K. Lester, et al. · Journal of Cystic Fibrosis

PDF

WS06.05 The volume of trapped air (VTA) from multiple breath washout (MBW) substantially underestimates the extent of trapped air (TA) demonstrated with spirometry-controlled computed tomography

2023 · C. Short, T. Semple, et al. · Journal of Cystic Fibrosis

PDF

EPS6.02 Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment

2023 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis

EPS6.06 Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with cystic fibrosis – The RECOVER study

2023 · P. McNally, K. Lester, et al. · Journal of Cystic Fibrosis

PDF

Works count: 26

Citation count: 9

H-index: 2

I10-index: